Results of Operations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 27, 2023   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 1.500% Senior Notes due 2023 ABBV23B New York Stock Exchange 1.375% Senior Notes due 2024 ABBV24 New York Stock Exchange 1.250% Senior Notes due 2024 ABBV24B New York Stock Exchange 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior Notes due 2028 ABBV28B New York Stock Exchange 2.125% Senior Notes due 2029 ABBV29 New York Stock Exchange 1.250% Senior Notes due 2031 ABBV31 New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐     Item 2.02  Results of Operations and Financial Condition   On October 27, 2023, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2023.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No.   Exhibit 99.1   Press Release dated October 27, 2023 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       ABBVIE INC.       Date: October 27, 2023 By: /s/ Scott T. Reents     Scott T. Reents     Executive Vice President,     Chief Financial Officer